The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis
Open accessAbstract
Stimulator of interferon genes (STING) has been shown to be critical for controlling antiviral responses as well as anti-tumor adaptive immunity, but little is known regarding its regulation in human tumors. Here, we report that STING signaling is recurrently suppressed in a wide variety of cancers, including colorectal carcinoma. Loss of STING signaling impeded DNA damage responses accountable for generating key cytokines that facilitate tissue repair and anti-tumor T cell priming, such as type I interferons (IFNs). Correspondingly, defective STING function was also highly predictive of effectual DNA-virus-mediated oncolytic activity. Thus, impaired STING responses may enable damaged cells to evade host immunosurveillance processes, although they provide a critical prognostic measurement that could help predict the outcome of effective oncoviral therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accordingly, cancer cells often inactivate the cGAS-STING pathway to evade immune detection (Xia et al., 2016).”
From Cytoplasmic DNA: sources, sensing, and role in aging and disease (2021) · cites this paper as Xia et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
Self-citationThe gut microbiota, bacterial metabolites and colorectal cancer
Louis, P., Hold, G. L., & Flint, H. J. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3344 · Cited by 2,925
Cancer treatment and survivorship statistics, 2014
Desantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,847
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 5×
“Tumors with defective STING-Signaling are sensitive to viral Oncolysis We have previously shown that loss of STING signaling in vitro or in vivo renders cells or mice, respectively, extremely sensitive to Herpes simplex virus (HSV) infection (Ishikawa and Barber, 2008; Ishikawa et al., 2009).”
BackgroundMethodInfluentialSelf-citationIntestinal inflammation targets cancer-inducing activity of the microbiota
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T.-J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., et al. (2012) · Science · doi:10.1126/science.1224820 · Cited by 2,263
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
Cited by
Sorted by citations
Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
cGAS surveillance of micronuclei links genome instability to innate immunity
Mackenzie, K. J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017) · Nature · doi:10.1038/nature23449 · Cited by 1,752
The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
Kwon, J., & Bakhoum, S. F. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0761 · Cited by 1,293
The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293
cGAS in action: Expanding roles in immunity and inflammation
Ablasser, A., & Chen, Z. J. (2019) · Science · doi:10.1126/science.aat8657 · Cited by 1,077
cGAS is essential for cellular senescence
Yang, H., Wang, H., Ren, J., Chen, Q., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705499114 · Cited by 1,009
The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment
Bakhoum, S. F. W., & Cantley, L. C. (2018) · Cell · doi:10.1016/j.cell.2018.08.027 · Cited by 742
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
The cGAS–STING pathway and cancer
Samson, N., & Ablasser, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00468-w · Cited by 740
cGAS-STING, an important pathway in cancer immunotherapy
Jiang, M., Chen, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., Ye, L., He, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00916-z · Cited by 647
Marcus, A., Mao, A. J., Lensink-Vasan, M., Wang, L., Vance, R. E., & Raulet, D. H. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.016 · Cited by 609
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 622
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 587
Linking cellular stress responses to systemic homeostasis
Galluzzi, L., Yamazaki, T., & Kroemer, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0068-0 · Cited by 556
Optimizing oncolytic virotherapy in cancer treatment
Harrington, K. J., Freeman, D. J., Kelly, E. J., Harper, J. A., & Soria, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 530
The host STING pathway at the interface of cancer and immunity
Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487
Glover, H. L., Schreiner, A., Dewson, G., & Tait, S. W. G. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01429-4 · Cited by 515
Interferons α and β in cancer: therapeutic opportunities from new insights
Borden, E. C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0011-2 · Cited by 428
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413
Zhou, Y., Fei, M., Zhang, G., Liang, W., Lin, W., Wu, Y., Piskol, R., Ridgway, J. B., McNamara, E., Huang, H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.01.014 · Cited by 406
Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis
Xia, T., Konno, H., & Barber, G. N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1404 · Cited by 397
Self-citationWang, Y., Deng, W., Li, N., Neri, S., Sharma, A., Jiang, W., & Lin, S. H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00185 · Cited by 385
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 372
Cancer Epigenetics, Tumor Immunity, and Immunotherapy
Cao, J. P., & Yan, Q. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.003 · Cited by 355
Mutant p53 Suppresses Innate Immune Signaling to Promote Tumorigenesis
Ghosh, M., Saha, S., Bettke, J. A., Nagar, R., Parrales, A., Iwakuma, T., van der Velden, A. W. M., & Martinez, L. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2021.01.003 · Cited by 355
STING pathway agonism as a cancer therapeutic
Flood, B. A., Higgs, E. F., Li, S., Luke, J. J., & Gajewski, T. F. (2019) · Immunological Reviews · doi:10.1111/imr.12765 · Cited by 340
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
Zheng, J., Mo, J., Zhu, T., Zhuo, W., Yi, Y., Hu, S., Yin, J., Zhang, W., Zhou, H., & Liu, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01250-1 · Cited by 344
The emerging field of oncolytic virus-based cancer immunotherapy
Ma, R., Li, Z., Chiocca, E. A., Caligiuri, M. A., & Yu, J. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.003 · Cited by 339
DNA Damage and Cancer Immunotherapy: A STING in the Tale
Reisländer, T., Groelly, F. J., & Tarsounas, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.026 · Cited by 325
Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity
Schadt, L., Sparano, C., Schweiger, N. A., Siliņa, K., Cecconi, V., Lucchiari, G., Yagita∥, H., Guggisberg, E., Saba, S., Naščáková, Z., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.065 · Cited by 299
Cytoplasmic DNA: sources, sensing, and role in aging and disease
Miller, K. N., Victorelli, S. G., Salmonowicz, H., Dasgupta, N., Liu, T., Passos, J. F., & Adams, P. D. (2021) · Cell · doi:10.1016/j.cell.2021.09.034 · Cited by 288
Molecular mechanisms of viral oncogenesis in humans
Krump, N. A., & You, J. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0064-6 · Cited by 311
Trial watch: STING agonists in cancer therapy
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289
Konno, H., Yamauchi, S., Berglund, A., Putney, R. M., Mulé, J. J., & Barber, G. N. (2018) · Oncogene · doi:10.1038/s41388-017-0120-0 · Cited by 281
Self-citationThe Cyclopeptide Astin C Specifically Inhibits the Innate Immune CDN Sensor STING
Li, S., Hong, Z., Wang, Z., Li, F., Mei, J., Huang, L., Lou, X., Zhao, S., Song, L., Chen, W., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.097 · Cited by 279
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H. D. P., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0106-z · Cited by 282
Wang, Q., Bergholz, J. S., Ding, L., Lin, Z., Kabraji, S. K., Hughes, M. E., He, X., Xie, S., Jiang, T., Wang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30568-1 · Cited by 275
STING activation in cancer immunotherapy
Su, T., Zhang, Y. L., Valerie, K. C., Wang, X., Lin, S., & Zhu, G. (2019) · Theranostics · doi:10.7150/thno.37574 · Cited by 262
Harnessing innate immune pathways for therapeutic advancement in cancer
Hu, A.-K., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. Q. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01765-9 · Cited by 286
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
Aval, L. M., Pease, J. E., Sharma, R., & Pinato, D. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103323 · Cited by 253
cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity
Wang, Z., Chen, J., Hu, J., Zhang, H., Xu, F., He, W., Wang, X., Li, M., Lu, W., Zeng, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127471 · Cited by 253
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Qiao, J. T., Cui, C., Qing, L., Wang, L., He, T., Yan, F., Liu, F. Q., Shen, Y. H., Hou, X., & Chen, L. (2017) · Metabolism · doi:10.1016/j.metabol.2017.09.010 · Cited by 245
Exploiting DNA Replication Stress for Cancer Treatment
Ubhi, T., & Brown, G. W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3631 · Cited by 245
Yang, K., Han, W., Jiang, X., Piffkó, A., Bugno, J., Han, C., Li, S., Liang, H. L., Xu, Z., Zheng, W., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01225-x · Cited by 224
cGAS–STING and Cancer: Dichotomous Roles in Tumor Immunity and Development
Ng, K. W., Marshall, E. A., Bell, J. C., & Lam, W. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.013 · Cited by 219
Decreased expression of STING predicts poor prognosis in patients with gastric cancer
Song, S., Peng, P., Tang, Z., Zhao, J., Wu, W., Li, H., Shao, M., Li, L., Yang, C., Duan, F., et al. (2017) · Scientific Reports · doi:10.1038/srep39858 · Cited by 219
An, X., Zhu, Y., Zheng, T., Wang, G., Zhang, M., Li, J., Ji, H., Li, S., Yang, S., Xu, D., et al. (2019) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.11.003 · Cited by 188
Zhang, Z., Zhou, H., Ouyang, X., Dong, Y., Sarapultsev, A., Luo, S., & Hu, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01252-z · Cited by 222
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 207
Role of the cGAS–STING pathway in cancer development and oncotherapeutic approaches
Khoo, L. T., & Chen, L. (2018) · The EMBO Reports · doi:10.15252/embr.201846935 · Cited by 204
Opposing Roles of Type I Interferons in Cancer Immunity
Boukhaled, G. M., Harding, S. M., & Brooks, D. G. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-031920-093932 · Cited by 208
Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells
Ahn, J., Xia, T., Rabasa, A., Betancourt, D. M., & Barber, G. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.027 · Cited by 194
Self-citationDNA-stimulated cell death: implications for host defence, inflammatory diseases and cancer
Paludan, S. R., Reinert, L. S., & Hornung, V. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-018-0117-0 · Cited by 187
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs
Rañoa, D. R. E., Parekh, A. D., Pitroda, S. P., Huang, X., Darga, T. E., Wong, A., Huang, L., Andrade, J., Staley, J. P., Satoh, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8420 · Cited by 184
Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 192
Old dogs, new trick: classic cancer therapies activate cGAS
Yum, S., Li, M., & Chen, Z. J. (2020) · Cell Research · doi:10.1038/s41422-020-0346-1 · Cited by 184
Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers
Elion, D. L., Jacobson, M. E., Hicks, D. J., Rahman, B., Sanchez, V. M., Ericsson, P. I. G., Fedorova, O., Pyle, A. M., Wilson, J. T., & Cook, R. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0730 · Cited by 178
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications
Shen, M., Jiang, X., Qiu, P., Oyang, L., Ren, Z., Wang, J., Peng, M., Zhou, Y., Deng, X., & Liao, Q. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01691-5 · Cited by 210
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers
Vanpouille‐Box, C., Formenti, S. C., & Demaria, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0037 · Cited by 177
KDM5 histone demethylases repress immune response via suppression of STING
Wu, L., Cao, J. P., Cai, W. L., Lang, S. M., Horton, J. R., Jansen, D. J., Liu, Z. Z., Chen, J. F.-Y., Zhang, M., Mott, B. T., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2006134 · Cited by 182
STING signaling and host defense against microbial infection
Ahn, J., & Barber, G. N. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0333-0 · Cited by 180
Self-citationNuclear Membrane Rupture and Its Consequences
Maciejowski, J., & Hatch, E. M. (2020) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-020520-120627 · Cited by 170
p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression
Ghosh, M., Saha, S., Li, J., Montrose, D. C., & Martinez, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.023 · Cited by 166
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166
The balance of STING signaling orchestrates immunity in cancer
Lanng, K. R. B., Lauridsen, E. L., & Jakobsen, M. R. (2024) · Nature Immunology · doi:10.1038/s41590-024-01872-3 · Cited by 179
Extrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway
Chen, Y., Shen, Y., Hsia, H.-Y., Tiang, Y. P., Sung, T.-L., & Chen, L. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3498 · Cited by 168
STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2
Zhang, L., Jiang, C., Zhong, Y., Sun, K., Jing, H., Song, J., Xie, J., Zhou, Y., Tian, M., Zhang, C., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01185-x · Cited by 174
Innate Immune Response to Cytoplasmic DNA: Mechanisms and Diseases
Hu, M., & Shu, H. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070119-115052 · Cited by 160
Cordova, A. F., Ritchie, C., Böhnert, V., & Li, L. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00440 · Cited by 157
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
Mender, I., Zhang, A., Ren, Z., Han, C., Deng, Y., Siteni, S., Li, H., Zhu, J., Vemula, A., Shay, J. W., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.020 · Cited by 149
Iracheta‐Vellve, A., Petrasek, J., Gyöngyösi, B., Satishchandran, A., Lowe, P., Kodys, K., Catalano, D., Calenda, C. D., Kurt‐Jones, E. A., Fitzgerald, K. A., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.736991 · Cited by 151
Marx, S., Maso, T. D., Chen, J.-W., Bury, M., Wouters, J., Michiels, C., & Calvé, B. L. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.018 · Cited by 151
Feng, X., Tubbs, A., Zhang, C., Tang, M., Sridharan, S., Wang, C., Jiang, D., Su, D., Zhang, H., Chen, Z., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019104036 · Cited by 152
The Crosstalk Between Hippo-YAP Pathway and Innate Immunity
Wang, S., Zhou, L., Ling, L., Meng, X., Chu, F., Zhang, S., & Zhou, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00323 · Cited by 143
TMEM173 variants and potential importance to human biology and disease
Patel, S., & Jin, L. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0029-9 · Cited by 146
de Queiroz, N. M. G. P., Xia, T., Konno, H., & Barber, G. N. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0504 · Cited by 144
Self-citationMitochondria at the interface between neurodegeneration and neuroinflammation
Bader, V., & Winklhofer, K. F. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.028 · Cited by 135
cGAS‐cGAMP‐STING: The three musketeers of cytosolic DNA sensing and signaling
Tao, J., Zhou, X., & Jiang, Z. (2016) · IUBMB Life · doi:10.1002/iub.1566 · Cited by 135
Zhang, C.-X., Ye, S., Ni, J., Cai, T., Liu, Y.-N., Huang, D.-J., Mai, H., Chen, Q.-Y., He, J., Zhang, X.-S., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0302-0 · Cited by 135
Tijhuis, A. E., Johnson, S. C., & McClelland, S. E. (2019) · Molecular Cytogenetics · doi:10.1186/s13039-019-0429-1 · Cited by 131
Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies
Iurescia, S., Fioretti, D. P., & Rinaldi, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00711 · Cited by 124
Guo, X., Ni, J., Liang, Z., Xue, J., Fenech, M. F., & Wang, X. (2018) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2018.11.001 · Cited by 127
Replication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response
Ragu, S., Matos-Rodrigues, G. E., & López, B. S. (2020) · Genes · doi:10.3390/genes11040409 · Cited by 131
Biochemistry, Cell Biology, and Pathophysiology of the Innate Immune cGAS–cGAMP–STING Pathway
Ritchie, C., Carozza, J. A., & Li, L. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-040320-101629 · Cited by 123
The role of cGAS-STING signalling in liver diseases
Chen, R., Du, J., Zhu, H., & Ling, Q. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100324 · Cited by 131
Exosome DNA: Critical regulator of tumor immunity and a diagnostic biomarker
Sharma, A., & Johnson, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29153 · Cited by 122
Prospects for combined use of oncolytic viruses and CAR T-cells
Ajina, A., & Maher, J. F. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0294-6 · Cited by 120
Sevenich, L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00163 · Cited by 121
Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy
Berger, G., Marloye, M., & Lawler, S. E. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.007 · Cited by 117
Lohard, S., Bourgeois, N., Maillet, L., Gautier, F., Fétiveau, A., Lasla, H., Nguyen, F., Vuillier, C., Dumont, A., Moreau‐Aubry, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13689-y · Cited by 120
Chromatin bridges, not micronuclei, activate cGAS after drug-induced mitotic errors in human cells
Flynn, P. J., Koch, P. D., & Mitchison, T. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103585118 · Cited by 118
The complementarity of DDR, nucleic acids and anti-tumour immunity
Kornepati, A. V. R., Rogers, C. M., Sung, P., & Curiel, T. J. (2023) · Nature · doi:10.1038/s41586-023-06069-6 · Cited by 117
Lv, H., Zong, Q., Chen, C., Lv, G., Xiang, W., Xing, F., Jiang, G., Yan, B., Sun, X., Ma, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-43743-9 · Cited by 117
STING, the Endoplasmic Reticulum, and Mitochondria: Is Three a Crowd or a Conversation?
Smith, J. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.611347 · Cited by 116
5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
Tian, J., Zhang, D., Kurbatov, V., Wang, Q., Wang, Y., Fang, D., Wu, L., Bosenberg, M., Muzumdar, M. D., Khan, S. A., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106065 · Cited by 114
Immune Diseases Associated with TREX1 and STING Dysfunction
Yan, N. (2017) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2016.0086 · Cited by 110
Metadata
- Authors
- Xia, T., Konno, H., Ahn, J., & Barber, G. N.
- Affiliations
- University of Miami (US)
- Corresponding author
- Barber, Glen N.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 14
- Issue
- 2
- Pages
- 282-297
- ISSN
- 2211-1247 (ISSN-L)
- PMC
- PMC4845097
- OpenAlex
- W2220279767
- Cited by
- 589
- References
- 50
- Citations by year
- 2026: 46 · 2025: 61 · 2024: 70 · 2023: 66 · 2022: 77 · 2021: 76 · 2020: 51 · 2019: 57 · 2018: 44 · 2017: 28 · 2016: 13
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cell Reports (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Sylvester Comprehensive Cancer Center, University of Miami Health Systems
- National Cancer Institute (R01CA194404)
- National Institute of Allergy and Infectious Diseases (R01AI079336)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- STING signaling, colorectal cancer, DNA damage response, type I interferon, tumor surveillance, DNA viruses, carcinogenesis, prognostic factors, tissue repair
- MeSH terms
- Animals, DNA Damage, Humans, Transfection, Colorectal Neoplasms, Signal Transduction, Mice, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
